

July 8, 2011

11:45 a.m.

Skanska awarded US biotech project worth USD 70 M, about SEK 445 M

Skanska USA Building has signed a contract with a leading Bay Area biotechnology company. The contract amounts to USD 70 M, about SEK 445 M, which will be included in order bookings for the second quarter 2011.

The scope of work will provide construction management. Skanska will also move services for the company's campus in the region. Work will commence this summer and continue over a three year period.

Skanska USA is one of the leading development and construction companies in the country, consisting of four business units: Skanska USA Building, which specializes in building construction; Skanska USA Civil, specialized in civil infrastructure; Skanska Infrastructure Development, which develops public-private partnerships; and Skanska Commercial Development, which develops commercial development projects in select U.S. markets. Headquartered in New York, Skanska USA has approximately 7,400 employees and its 2010 revenues were SEK 34.3 billion.

For further information, please contact:

Jay Weisberger, Communications Manager, Skanska USA,
tel +1 206 494 5469

Edvard Lind, Group Press Officer, Skanska AB, Tel: +46 (0)10-448 88 08

Direct line for media: +46 10 448 88 99

This and previous releases can also be found at www.skanska.com

Skanska AB may be required to disclose the information provided herein pursuant to the Securities Markets Act.

Skanska is one of the world's leading project development and construction groups with expertise in construction, development of commercial and residential projects and public-private partnerships. Based on its global green experience, Skanska aims to be the clients' first choice for Green solutions. The Group currently has 52,000 employees in selected home markets in Europe, in the US and Latin America. Headquartered in Stockholm, Sweden and listed on the Stockholm Stock Exchange, Skanska's sales in 2010 totalled SEK 122 billion.